PMID: 6433026Jul 1, 1984

Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds

Journal of Molecular and Cellular Cardiology
S J Coker


The administration of the thromboxane synthetase inhibitor UK38485, 3 mg/kg i.v. 30 min prior to occlusion of the LAD in chloralose-anaesthetized dogs reduced the number of extrasystoles that occurred in the first 30 min of ischaemia from 832 +/- 158 in controls to 193 +/- 126 (P less than 0.01). VF induced by the release of the occlusion after 40 min was also markedly reduced from seven out of nine in controls to two out of seven in the drug group. UK38485 did not alter blood gases or haemodynamics prior to LAD occlusion and the changes in PO2, PCO2 and pH in blood draining from the ischaemic myocardium during occlusion were similar in control and drug-treated dogs. The haemodynamic changes induced by coronary artery occlusion were attenuated by UK38485. This drug also prevented the thromboxane release that normally occurs during acute myocardial ischaemia but did not suppress prostacyclin release. These results provide further evidence in support of the hypothesis that thromboxane is arrhythmogenic during acute myocardial ischaemia and is a particularly important contributory factor in reperfusion-induced VF.


May 1, 1988·Cardiovascular Drugs and Therapy·J R Parratt
May 1, 1994·Agents and Actions·S D SethS K Maulik
Jan 1, 1992·European Journal of Clinical Pharmacology·R F BerntsenH Olsen
Jan 20, 1987·European Journal of Pharmacology·C L Wainwright, J R Parratt
Dec 10, 1991·European Journal of Pharmacology·P Salinas, S Barrigón
Feb 1, 1993·The International Journal of Biochemistry·T Siminiak, T Ozawa
Jan 1, 1985·Molecular Aspects of Medicine·J H BottingM J Walker
Jan 1, 1990·Free Radical Biology & Medicine·M BernierD J Hearse
Apr 1, 2008·Pharmacology & Therapeutics·Norimichi Nakahata
Nov 24, 2005·Prostaglandins & Other Lipid Mediators·Vincent Tchana-SatoPhilippe Kolh
Oct 1, 1989·Prostaglandins, Leukotrienes, and Essential Fatty Acids·E F SmithJ W Egan
Feb 1, 1987·Circulation Research·H H HolzgrefeS Bunting
Dec 13, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Michael J WackerJames A Orr
Sep 1, 1985·British Journal of Pharmacology·G R BullockC L Wainwright
Nov 9, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·Harold J TingFadi T Khasawneh

Related Concepts

Cardiac Arrhythmia
Carbon Dioxide
Sinus Node Artery
Canis familiaris
Hydrogen-Ion Concentration

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.


Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.